Solvay Settles Estratest False Marketing Suit For $16M

Law360, New York (March 18, 2010, 3:38 PM EDT) -- A federal judge has granted final approval to a $16.5 million class action settlement that will end a lawsuit accusing Solvay Pharmaceuticals Inc. of falsely marketing menopause-treating drugs as if they had been approved by the U.S. Food and Drug Administration.

Judge Richard Kyle of the U.S. District Court for the District of Minnesota signed off on the settlement Tuesday. Class members include people who purchased Solvay's Estratest or Estratest H.S. hormone replacement therapy drugs in the U.S., excluding California, since March 8, 1998.

As of...
To view the full article, register now.